Figure 6.

Clinical response in a patient with KRAS-mutant spindle cell sarcoma NOS.

(A) Patient clinical history. (B) Computed tomogrpahy scans of lesion 3 (mass superior to pancreatic head, green arrow, see also Supplementary Table S4, available at https://doi.org/10.1016/j.annonc.2020.10.483, for blots) of the patient at recurrence, before and after pazopanib treatment; before and during CCT3833 treatment. 0 = baseline (pretreatment) before each treatment; percentage of sum of all marker lesions is reported on the bottom right of each scan as per RECIST 1.1 criteria (Table 1). Hypodensity within the lesion seen on scan at cycle 6 and 8 suggests necrosis due to treatment response (white arrowhead). NOS, not otherwise specified; PD, progressive disease; unconfirmed PR, unconfirmed partial response; SD, stable disease.